AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 6 - (NewsRx.com & NewsRx.net) -- DOR BioPharma, Inc., (DOR) announced that it has initiated a program to produce orally administered vaccines to protect against exposure to biological agents that can potentially be used in bioterrorist attacks.
The initial candidate vaccine is against ricin toxin, a highly potent biological toxin that is relatively easy to produce, store, and disperse and therefore a candidate for bioterrorism.
DOR stated, "Orally administered nonlive vaccines may represent a preferred method of protecting our troops and population from certain biological threats given their potential ease of administration and distribution, low cost and speed of production, prolonged shelf-life, mucosal and systemic protection and avoidance of use of live pathogens."
Through its interest in its Innovaccines joint venture, DOR has an exclusive license to dominant intellectual property covering the oral delivery of encapsulated nonlive vaccines, including U.S. Patent Nos. 6,024,983; 5,942,252; 5,853,763; 5,820,883; 5,814,344; and 5,811,128 as well as European patents EP 0 266 119 and EP 0 333 523.
According to results recently published by researchers at the United ...
Source: HighBeam Research, Development of oral biological defense vaccines initiated.